Sector footprint
$407.3M in exports
Reported chemicals exports in 2024 across 26 qualifying HS6 products.
Sector export playbook ยท HS 28-38
Kazakhstan Chemicals exports
where capability meets demand
Explore Kazakhstan's HS 28-38 product portfolio, buyer markets, growth signals, and diversification opportunities. Use this guide to prioritize research, not to treat calculated indicators as guaranteed sales.
Sector exports$407.3M2024 reported value
Products26Qualifying HS6 products
Buyer markets24Markets represented
Average CAGR+137.7%Product-level growth signal
Global sector size$480.4BReported buyer imports
Chemicals capability
How strong is Kazakhstan in this sector?
Compare exporter scale with product breadth, buyer demand, growth, and destination reach. A large sector does not remove the need for product, compliance, pricing, and buyer validation.
Global demand
$480.4B buyer imports
The sector's reported buyer import base provides context for product and market prioritization.
How to use the guide
Find the next credible move
Start with products that combine demand and exporter capability, then validate standards, route economics, buyers, and competition.
Product portfolio
Which products anchor the sector?
Each HS6 product is ranked by calculated opportunity and shown with reported market size, exporter exports, growth, and destination reach.
| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
|---|---|---|---|---|---|---|
| HS 300490Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $286.3B | $20.1M | $109.0B | +4.3% | 18 | +0.0% |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | $27.1B | $20.7M | $17.9B | +30.9% | 9 | +0.3% |
| HS 300215Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $40.5B | $45.8K | $17.0B | +24.8% | 5 | +0.0% |
| HS 284190Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $6.6B | $1.0M | $9.7B | +3.8% | 4 | +0.0% |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $20.4B | $109.1K | $8.8B | +22.2% | 5 | +0.0% |
| HS 382200Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $18.7B | $819.0K | $8.3B | +73.3% | 5 | +0.0% |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $10.9B | $35.3K | $7.8B | +12.9% | 4 | +0.0% |
| HS 290243Cyclic hydrocarbons: p-xylene | $8.5B | $22.7M | $6.2B | +25.2% | 1 | +0.3% |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $11.3B | $139.8K | $6.0B | +22.2% | 2 | +0.0% |
| HS 330300Perfumes and toilet waters | $8.5B | $12.6K | $5.0B | -12.1% | 3 | +0.0% |
| HS 293379Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $1.4K | $4.8B | +2847.8% | 1 | +0.0% |
| HS 293499Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $5.8B | $8.9K | $4.6B | +2017.4% | 1 | +0.0% |
| HS 290220Cyclic hydrocarbons: benzene | $4.1B | $2.6M | $3.5B | +34.5% | 1 | +0.1% |
| HS 293359Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $3.5B | $5.3K | $3.2B | +2318.3% | 1 | +0.0% |
| HS 284420Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $5.9B | $37.4M | $3.0B | +8.9% | 2 | +1.5% |
| HS 382319Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $143.3K | $1.9B | +30.4% | 1 | +0.0% |
| HS 284690Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $167.6K | $1.5B | -7.6% | 1 | +0.0% |
| HS 300670Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $27.7 | $1.4B | -15.0% | 1 | +0.0% |
| HS 310420Fertilizers, mineral or chemical: potassic, potassium chloride | $3.3B | $81.8 | $1.4B | -21.7% | 1 | +0.0% |
| HS 321590Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $24.0K | $1.1B | +70.6% | 1 | +0.1% |
| HS 284410Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.6B | $301.4M | $1.1B | +10.0% | 1 | +19.2% |
| HS 300290Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $8.0 | $1.0B | -14.2% | 1 | +0.0% |
| HS 300220Vaccines: for human medicine | $1.5B | $12.1K | $1.0B | -26.7% | 1 | +0.0% |
| HS 300390Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $2.0B | $124.4 | $981.1M | -12.5% | 1 | +0.0% |
| HS 280461Silicon: containing by weight not less than 99.99% of silicon | $839.5M | $51.6 | $927.8M | -70.2% | 1 | +0.0% |
| HS 293339Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $1.6B | $4.1K | $871.2M | +1818.7% | 1 | +0.0% |
Best markets
Where does sector demand concentrate?
Markets are ranked by calculated opportunity across the qualifying products in this sector view.
USA
USA, Puerto Rico and US Virgin Islands
9 products represented in the sector.
$35.4B$112.0B reported buyer importsCHN
China
12 products represented in the sector.
$34.4B$57.1B reported buyer importsCHE
Switzerland, Liechtenstein
3 products represented in the sector.
$33.3B$51.7B reported buyer importsDEU
Germany
12 products represented in the sector.
$33.2B$77.9B reported buyer importsNLD
Netherlands
4 products represented in the sector.
$12.9B$26.7B reported buyer importsSVN
Slovenia
2 products represented in the sector.
$12.8B$9.6B reported buyer importsGBR
United Kingdom
3 products represented in the sector.
$8.1B$18.9B reported buyer importsBEL
Belgium
1 products represented in the sector.
$7.0B$18.6B reported buyer importsFRA
France
4 products represented in the sector.
$6.6B$17.9B reported buyer importsESP
Spain
2 products represented in the sector.
$6.6B$13.4B reported buyer importsCAN
Canada
2 products represented in the sector.
$4.9B$9.3B reported buyer importsITA
Italy
1 products represented in the sector.
$4.9B$14.7B reported buyer importsGrowth stars
Which products show the strongest growth?
Average product-level CAGR is a screening signal. Confirm the latest trend, base effects, buyer quality, and commercial feasibility before acting.
| Product | Average CAGR | Opportunity | Markets |
|---|---|---|---|
| HS 293379Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | +2847.8% | $4.8B | 1 |
| HS 293359Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | +2318.3% | $3.2B | 1 |
| HS 293499Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | +2017.4% | $4.6B | 1 |
| HS 293339Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | +1818.7% | $871.2M | 1 |
| HS 382200Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | +73.3% | $8.3B | 5 |
| HS 321590Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | +70.6% | $1.1B | 1 |
| HS 290220Cyclic hydrocarbons: benzene | +34.5% | $3.5B | 1 |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | +30.9% | $17.9B | 9 |
| HS 382319Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | +30.4% | $1.9B | 1 |
| HS 290243Cyclic hydrocarbons: p-xylene | +25.2% | $6.2B | 1 |
Diversification opportunities
Which products reach the widest buyer base?
Destination count is a simple breadth indicator. It does not measure destination concentration or guarantee resilience.
HS 300490
Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale
18 markets$109.0B calculated opportunityHS 382499
Chemical products, mixtures and preparations: n.e.c. heading 3824
9 markets$17.9B calculated opportunityHS 300215
Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale
5 markets$17.0B calculated opportunityHS 330499
Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations)
5 markets$8.8B calculated opportunityHS 382200
Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material
5 markets$8.3B calculated opportunityHS 284190
Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841
4 markets$9.7B calculated opportunityHS 300439
Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale
4 markets$7.8B calculated opportunityHS 330300
Perfumes and toilet waters
3 markets$5.0B calculated opportunityFrequently asked questions
Using the Chemicals export playbook
Practical guidance for interpreting sector scale, growth, product breadth, and buyer markets.
How strong is Kazakhstan in this sector?
Compare sector exports, product breadth, buyer markets, growth, and global demand. These signals identify research priorities rather than guarantee market access.
What are growth stars?
Products with higher average reported growth in the screened rows. Validate the time period, base effects, buyer demand, and current exporter position.
What does diversification mean here?
Products reaching more buyer markets in the screened data. Destination breadth is useful context but does not replace concentration, route, or buyer analysis.
Data source
OECD trade statistics with CEPII context
OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). OECD BIMTS is the primary trade series for this view. Supporting bilateral trade context uses CEPII BACI bilateral trade flows (202601) under Etalab 2.0 Open Licence. Yugalinks presents derived views of reported observations and calculated indicators. Data terms: OECD Terms & Conditions.